Next generation of small molecules in inflammatory bowel disease

Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease

(2016) G. Monteleone et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Revisiting the regulatory roles of the TGF-β family of cytokines

(2016) Keshi Fujio et al.   AUTOIMMUNITY REVIEWS

Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity

(2016) F L Scott et al.   BRITISH JOURNAL OF PHARMACOLOGY

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents

(2016) Pauline Wils et al.   Clinical Gastroenterology and Hepatology

Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases

(2016) James Harnett et al.   CLINICAL THERAPEUTICS

Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster

(2016) Kunihiro Yamaoka   DRUG SAFETY

Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease

(2016) Lieven Pouillon et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators

(2016) Pierre-Eric Juif et al.   Expert Opinion on Drug Metabolism & Toxicology

Will novel oral formulations change the management of inflammatory bowel disease?

(2016) Ole Haagen Nielsen et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

856 Efficacy and Safety of Oral Tofacitinib for Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial

(2016) Geert R. D'Haens et al.   GASTROENTEROLOGY

855 Efficacy and Safety of Tofacitinib for Oral Induction Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial

(2016) Julian Panés et al.   GASTROENTEROLOGY

857 Ozanimod Induces Histological Response and Remission: Results From the TOUCHSTONE Study, a Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis

(2016) William Sandborn et al.   GASTROENTEROLOGY

AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial

(2016) M. Scott Harris et al.   Journal of Crohns & Colitis

OP020. Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn’s disease: interim analysis from the Phase 2 FITZROY study

(2016)   Journal of Crohns & Colitis

Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial

(2016) Jeffrey A Cohen et al.   LANCET NEUROLOGY

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

(2016) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Small molecules with anti-inflammatory properties in clinical development

(2016) Thomas Hanke et al.   PHARMACOLOGY & THERAPEUTICS

Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS)

(2016) Axel Meissner et al.   Multiple Sclerosis and Related Disorders

Loss of Response to Anti-TNFs: Definition, Epidemiology and Management

(2016) Giulia Roda et al.   Clinical and Translational Gastroenterology

Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases

(2016) Daniele D’Ambrosio et al.   Therapeutic Advances in Chronic Disease

A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases

(2015) Eleni Vangeli et al.   ADVANCES IN THERAPY

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

(2015) Jeffrey R Curtis et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials

(2015) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C

(2015) Ivan Gentile et al.   Expert Opinion on Drug Discovery

Targeting SMAD7 in Crohn’s Disease by Mongersen: Therapeutic Revolution Under Way?

(2015) Silvio Danese et al.   GASTROENTEROLOGY

Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease

(2015) Joana Torres et al.   GASTROENTEROLOGY

Laquinimod ameliorates spontaneous colitis in interleukin-10-gene-deficient mice with improved barrier function

(2015) Jing Sun et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy

(2015) Richard L. Proia et al.   JOURNAL OF CLINICAL INVESTIGATION

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

(2015) Hervé Bachelez et al.   LANCET

Oral SMAD7 Antisense Drug for Crohn's Disease

(2015) Severine Vermeire   NEW ENGLAND JOURNAL OF MEDICINE

Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn’s Disease

(2015) Giovanni Monteleone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review

(2015) Fanny Depont et al.   PLoS One

What is the future of targeted therapy in rheumatology: biologics or small molecules?

(2014) Attila Mócsai et al.   BMC Medicine

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

(2014) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis

(2014) Michel Varrin-Doyer et al.   EXPERIMENTAL NEUROLOGY

Anti–Tumor Necrosis Factor-α Monotherapy Versus Combination Therapy with an Immunomodulator in IBD

(2014) Parambir S. Dulai et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

A phase II study of laquinimod in Crohn's disease

(2014) Geert D'Haens et al.   GUT

Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

(2014) James D. Clark et al.   JOURNAL OF MEDICINAL CHEMISTRY

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

(2014) Eun Bong Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials: A Systematic Review and Meta-Analysis

(2014) Alejandro Souto et al.   Arthritis & Rheumatology

Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

(2014) Stanley Cohen et al.   Arthritis & Rheumatology

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2013) William J. Sandborn et al.   GASTROENTEROLOGY

Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial

(2013) Laurent Peyrin-Biroulet et al.   GUT

Adherence to Anti-TNF Therapy in Inflammatory Bowel Diseases

(2013) Anthony Lopez et al.   INFLAMMATORY BOWEL DISEASES

The Extra Burden of Infliximab Infusions in Inflammatory Bowel Disease

(2013) Anthony Buisson et al.   INFLAMMATORY BOWEL DISEASES

The burden of inflammatory bowel disease in Europe

(2013) Johan Burisch et al.   Journal of Crohns & Colitis

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease

(2013) Ole Haagen Nielsen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAKs and STATs in Immunity, Immunodeficiency, and Cancer

(2013) John J. O'Shea et al.   NEW ENGLAND JOURNAL OF MEDICINE

Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease

(2013) Mehmet Coskun et al.   PHARMACOLOGICAL RESEARCH

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study

(2012) Mirthe Emilie van der Valk et al.   GUT

Mucosal healing in inflammatory bowel diseases: a systematic review

(2012) Markus F Neurath et al.   GUT

Phase I Clinical Trial of Smad7 Knockdown Using Antisense Oligonucleotide in Patients With Active Crohn's Disease

(2012) Giovanni Monteleone et al.   MOLECULAR THERAPY

Fingolimod for Multiple Sclerosis

(2012) Daniel Pelletier et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis

(2012) Giancarlo Comi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review article: loss of response to anti-TNF treatments in Crohn’s disease

(2011) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

(2011) Vincent Billioud et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Transforming growth factor-beta type 1 receptor (ALK5) and Smad proteins mediate TIMP-1 and collagen synthesis in experimental intestinal fibrosis

(2011) Carlos Medina et al.   JOURNAL OF PATHOLOGY

Insight into the mechanism of laquinimod action

(2011) W. Brück et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes

(2010) Richard J. Riese et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

(2010) Matthieu Allez et al.   Journal of Crohns & Colitis

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis

(2010) Christiane Wegner et al.   JOURNAL OF NEUROIMMUNOLOGY

An update on sphingosine-1-phosphate and other sphingolipid mediators

(2010) Henrik Fyrst et al.   Nature Chemical Biology

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Health related quality of life in inflammatory bowel disease: The impact of surgical therapy

(2010) Konstantin Umanskiy   WORLD JOURNAL OF GASTROENTEROLOGY

Sphingosine 1-Phosphate Receptor Signaling

(2009) Hugh Rosen et al.   Annual Review of Biochemistry

Infliximab therapy for patients with inflammatory bowel disease: 10years on

(2009) Gert Van Assche et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules

(2009) David Marsolais et al.   NATURE REVIEWS DRUG DISCOVERY

Clinical implications of mucosal healing for the management of IBD

(2009) Guillaume Pineton de Chambrun et al.   Nature Reviews Gastroenterology & Hepatology

Inflammatory Bowel Disease

(2009) Clara Abraham et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blockade of transforming growth factor   upregulates T-box transcription factor T-bet, and increases T helper cell type 1 cytokine and matrix metalloproteinase-3 production in the human gut mucosa

(2008) A. Di Sabatino et al.   GUT

Medication Compliance and Persistence: Terminology and Definitions

(2007) Joyce A. Cramer et al.   VALUE IN HEALTH